- $250.84m
- $234.90m
- $4.41m
Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln
Brief: Ocugen Inc - U.S. Court Granted Co's Motion To Dismiss Securities Class Action Lawsuit - SEC Filing
Ocugen Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Ocugen, Inc. Announces First Patient Dosed In Phase 2/3 Gardian3 Pivotal Confirmatory Trial For Ocu410st—Novel Modifier Gene Therapy Candidate For Stargardt Disease
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Brief: Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea
Brief: Ocugen Announces Rare Pediatric Disease Designation Granted For Ocu410st—Modifier Gene Therapy For The Treatment Of Stargardt Disease
Ocugen Inc reports results for the quarter ended March 31 - Earnings Summary
Ocugen Inc expected to post a loss of 6 cents a share - Earnings Preview
Ocugen Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification
Ocugen Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Ocugen Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Brief: Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial Of Ocu400
Brief: Ocugen Inc - On Dec 31, 2024 Receives Nasdaq Notice For Bid Price Deficiency
Brief: Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st
Brief: Ocugen Announces Compelling Preliminary Data For Ocu410—A
Brief: Ocugen Inc - Appointed Ramesh Ramachandran To Serve As Co's Principal Financial Officer
Brief: Ocugen Provides Business Update With Third Quarter 2024 Financial Results